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Abstract 
Recent investigations have highlighted that therapeutic artificial microRNAs could be promising candidates for 
cancer therapy through the modulation of tumor promoter or suppressor. MEK kinase 1 (MEKK1) is expressed by 
mitogen-activated kinase kinase kinase 1 (MAP3K1), an important kinase that links Ras activation to MAPK signaling. 
In the present study, we showed that synthetic MAP3K1-targeting artificial miRNA may provide considerable benefi-
cial effects in the prevention of breast cancer growth and metastasis. We showed that MEKK1 was highly expressed 
in human breast cancer specimens, compared with adjacent normal tissues. Using a miRNA-expressing lentivirus 
system, we delivered a artificial miRNA (Map3k1 amiRNA) that targets MAP3K1 into 4T1 breast cancer cells and inves-
tigated the impact of MAP3K1-targeting miRNA on the growth and invasive behavior of breast cancer in vitro and 
in vivo. We found that overexpression of Map3k1 amiRNA led to impaired activities of p-ERK and p-p38. In addition, 
Map3k1 amiRNA induced marked proliferative impairment and invasive attenuation in breast cancer cells. However, 
Map3k1 amiRNA did not have evident influence on the apoptotic response of 4T1 cells. Moreover, using in vivo nude 
mice model, we identified that Map3k1 amiRNA attenuated tumor growth and lung metastasis of breast cancer cells. 
Taken together, our findings explicitly indicated that MEKK1 exerted important oncogenic property in breast cancer 
development, and MAP3K1-targeting artificial miRNA may provide promising therapeutic effects in the treatment of 
breast cancer.
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Background
Breast cancer represents the most frequent cancer 
among women and a leading cause of cancer-associated 
mortality around the world. It is estimated that there are 
annually 1.7 million breast cancer cases worldwide, with 
522,000 deaths (Ferlay et al. 2015). Despite the fact that 
vigorous investigations have been conducted by both 
basic scientists and clinical researchers, the prognosis 
of breast cancer remains unfavorable, mainly attributed 
to late diagnosis and limited therapeutic options (Farazi 
et  al. 2013). In addition, the adverse effects of existing 
therapies restrict their clinical merits in patients (Cuzick 
et al. 2011). Currently, a promising strategy of breast can-
cer therapy is to develop molecular target therapy, which 
has been proved to exert significant beneficial effects in 
breast cancer treatment. However, the molecular mecha-
nisms underlying breast cancer development remains 
not completely understood. Therefore, the clarification 
of therapeutic targets would benefit the development of 
novel breast cancer therapies.
Breast tumorigenesis involves complex molecular 
mechanisms. A variety of important cellular signal-
ing pathways have been critically implicated in the ini-
tiation and progression of breast cancer, such as MAPK 
cascades, Wnt/β-catenin, PI3K/AKT etc. From their 
discoveries, MAPK signaling has been a focus of cancer 
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investigations, including breast cancer (Wagner and 
Nebreda 2009). MAPKs are a family of typical serine-
threonine kinases and are divided into three major 
MAPK subfamilies, namely p38, JNK and ERK kinases. 
MAPKs are typical kinase members that are activated 
through upstream kinase cascades. MEKK1 was ini-
tially identified as a kinase that facilitates the activation 
of MEK and MAPK kinases (Yan et  al. 1994). Later on, 
it was reported that MEKK1 may phosphoryate IκBα 
and IκBβ kinase complexes, leading to consequent 
NF-κB activation (Lee et  al. 1998). M Russell reported 
that MEKK1 interacted directly with Ras, implying that 
MEKK1 may be a downstream effector of Ras signaling 
(Russell et  al. 1995). Accumulating data have suggested 
a crucial involvement of MEKK1 in tumor biology. For 
example, blockage of MEKK1 inhibited the survival, 
invasion and migration of human pancreatic cancer cells 
(Hirano et  al. 2002; Su et  al. 2009). Lysophosphatidic 
acid promotes ovarian cancer cell migration through 
Ras-MEKK1 signaling (Bian et al. 2004). Rangaswami H 
reported that Osteopontin triggered the growth and lung 
metastasis of melanoma via MEKK1-dependent MMP-9 
expression (Rangaswami and Kundu 2007). Interest-
ingly, mammary MEKK1-deficient mice exhibit no dif-
ference in tumor initiation. However, the dissemination 
and metastasis of breast cancer is significantly delayed in 
MEKK1-deficient mice (Cuevas et al. 2006). These find-
ings conceivably indicate that MEKK1 plays a facilitating 
role in the development of diverse tumor types. How-
ever, the expression pattern and physiological signifi-
cance of MEKK1 in human breast cancer remains to be 
elucidated.
Recent investigations have pointed to key roles of 
microRNAs (miRNAs) in the regulation of cellular sign-
aling and cancer biology (Farazi et al. 2013; Miska 2005). 
It has been well-established that miRNAs modulates the 
expression of various signaling transducers through bind-
ing to their mRNA 3′-terminal and inducing rapid decay 
of the mRNAs. As such, the utility of synthetic miR-
NAs as candidate targeted therapy has been proposed 
as a promising therapy of human diseases (Garofalo and 
Croce 2011). Kota J reported that the delivery of synthetic 
therapeutic miR-26a induces cell-cycle arrest in liver can-
cer cells through targeting Cyclin D2 and E1. Notably, 
they uncovered that in  vivo systemic administration of 
miR-26a hindered tumor growth, induced tumor-spe-
cific apoptosis and protected mice from hepatocellular 
carcinoma progression with no cytotoxic effects (Kota 
et  al. 2009). In addition to endogenous miRNA, artifi-
cially designed miRNAs that specifically target known 
oncogenes have attracted significant research atten-
tion. Masashi Idogawa reported that combined expres-
sion of p53 and artificial p21-targeting miRNA induced 
apparent apoptosis of colon cancer cells in vivo (Idogawa 
et al. 2009). The delivery of synthetic miRNAs has report-
edly exerted powerful tumor-suppressive effects in many 
other cancer types, such as gastric cancer, bladder can-
cer and melanoma (Li et al. 2006; Liu et al. 2012a, b). In 
breast cancer, it was also found that targeting CXCR4 
using artificial miRNA blocked the invasion and metas-
tasis of breast cancer cells (Liang et  al. 2007). Artificial 
miRNA-mediated MTDH knockdown inhibits the pro-
liferation, motility and migration of breast cancer cells 
(Wang et al. 2012). These findings together suggest that 
artificially designed miRNA may be a valuable approach 
in the treatment of breast cancer.
Given the information mentioned above, we analyzed 
the expression of MEKK1 in human breast cancer speci-
mens, and designed an artificial miRNA to specifically 
suppress the expression of MEKK1 and investigated the 
impact of miRNA-mediated MAP3K1 silencing on breast 
cancer physiology. We found that MEKK1 was highly 
expressed in breast cancer tissues, compared with adja-
cent normal ones. Moreover, we revealed that blockage 
of MEKK1 using artificial Map3k1 amiRNA suppressed 
the growth, lung metastasis and invasion of breast cancer. 
Our findings implicated that MAP3K1-targeting miRNA 




Murine breast carcinoma 4T1 cells and Human breast 
cancer cell lines, MCF-7 and MDA-MB-231 were pur-
chased from ATCC. The cells were maintained in 
RPMI-1640 medium (Gibco) supplemented 10  % fetal 
bovine serum (Hyclone). Cells were grown at 37 ℃ in a 
humidified incubator with 5  % CO2 atmosphere. Cells 
were grown at an exponential growth rate and harvested 
using 0.1  % trypsin–EDTA when cultures are approxi-
mately 80  % confluent. Cells were transfected using 
Lipofectamine 2000 (invitrogen) according to the manu-
facturer’s instruments.
The design of MAP3K1‑targeting amiRNA
MAP3K1 gene silencing was achieved by using a vector-
based system to produce artificial miRNA. The amiRNA 
expression vector (pcDNA™6.2-GW/EmGFP-miR) was 
a gift from Dr. Sun HuaiChang, yangzhou university. 
We got the sequence of mice MAP3K1 gene from NCBI 
database (Accession number:NM_011945.2), with the 
help of INVITROGEN Block-iT RNAi Designer soft-
ware, we analysed the MAP3K1 sequence and synthesis 
five candidate miRNA sequences with the highest star-
rating (data not shown). Furthermore, Map3k1 amiRNA 
sequence was subcloned into the eGFP-GV273 vector 
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and lentivirus was packed using the Lentivector Expres-
sion Systems (GENECHEM, Shanghai, China).
Quantitative real time PCR analysis
Total RNA was isolated from breast cancer cells by using 
Trizol (invitrogen), and cDNA was generated by reverse 
transcription system kit (invitrogen). Real-time PCR 
was used to detect relative gene expression using SYBR-
Green real-time PCR mixes (Roche). GAPDH was used 
as the internal control, and the expression difference of 
MAP3K1 gene between every groups was analyzed by 
statistical software Graphpad prism 5.
Western blot analysis
Total protein was isolated from breast cancer cells using 
RIPA buffer containing 1  % PMSF, protein concentra-
tion was determined using a BCA protein assay kit 
(Beyotime, China). Protein samples were run in a 6  % 
seperating gel, and then transferred onto a nitrocellulose 
membrane. The membranes were blocked for 2 h at 4 ℃ 
with Tris-buffered saline-Tween 20 (TBST) containing 
5  % skimmed milk, and probed with primary antibod-
ies angainst MEKK1 (Santa Cruz), ERK and P-ERK (Cell 
signaling technology, CST), JNK and P-JNK (CST), P38 
and p-p38 (CST), and internal control GAPDH (Santa 
Cruz). Antibodies were diluted in TBST containing 5 % 
skimmed milk. After 12 h incubation at 4 ℃, the mem-
branes were washed in TBST 10  min for three times. 
Then, the membrane was incubated with Goat Anti-Rab-
bit IRDye®800CW (ODYSSEY) for 2 h at room tempera-
ture. After additional washes, the protein bands were 
visualized by ODYSSEY System.
Immunofluorescence cell staining
The cells growing on the glass slide were fixed by 4  % 
paraformaldehyde, washed in PBS for 20  min, and then 
permeablized in 0.1  % Triton X-100/TBS for 10  min. 
Thereafter, the cells were blocked using 10 % goat serum 
for 1  h. After washing, slides were incubated with anti-
bodies to MEKK1(Santa CRUZ, 1:200) overnight at 4 ℃. 
After washing, the cells were incubated with Cy3-conju-
gated anti-goat antibodies (Jackson ImmunoResearch) 
and 4,6-diamidino-2-phenylindole (DAPI) for 2 h. Images 
were captured using a Zeiss Axiovert microscope. EdU 
(Ribobio) and TUNEL (Promega) assays were performed 
according to manufacturers recommendations.
H&E and immunohistochemistry
Mammary and lung tissues were fixed in 4 % paraform-
aldehyde and embedded in paraffin for sectioning. Next, 
the sections were subjected to HE staining in accord-
ance with the standard HE protocol. Breast cancer clini-
cal pathologic specimens (provided by AFFINIATED 
HOSPITAL OF NANTONG NUNIVERSITY) were 
immunostained with an anti-MEKK1 antibody (Santa 
Cruz, 1:100). Then, SP immunohistochemical stain-
ing kits was used according to manufacturers protocol 
(ZSGB-BIO).
Migration and invasion assay
Wound-healing experiment was employed to detect the 
migration ability of 4T1 cells in  vitro. 4T1 cells were 
transfected with Map3k1 amiRNA-3 or contol-amiRNA. 
When the cells reached 60  % confluence, 1  ml tip was 
used to scratch about 2 mm region along the plate Cen-
tral line and the medium was replaced into serum-free 
medium. The cells were incubated at 37 ℃ for an addi-
tional 24  h. The images of cells were capture by Zeiss 
Axiovert microscope. The number of cells migrated to 
scratch region were analyzed to compare the migration 
ability of 4T1cells.
The invasion ability of 4T1 cells was assessed by Tran-
swell (Corning) smeared with Matrigel (BD) assay. 4T1 
cells transfected with Map3k1 amiRNA-3 or contol 
amiRNA were cultivated in serum-free medium, wherein 
5  ×  105 cells were planted to invade through a filter 
(8  μm) toward 5  % serum-containing medium for 24  h. 
Thereafter, the invading cells were stained with Wright’s 
stian and counted for comparing the invasion ability of 
4T1 cells.
Colony formation assay
A suspension of 4T1 cells (5 × 103 cells) was prepared in 
0.35 % agar, which were added to a 6 cm plate over a base 
agar layer (0.6 %). Overlayed agar changed once a week, 
plates were incubated at 37 ℃ in a humidified incubator 
for 2  weeks. At termination, the colonies were stained 
with Crystal Violet and counted on a dissecting micro-
scope. Positive colonies were defined as clusters consist-
ing of more than 50 cells.
Tumorigenesis and lung metastasis model
BALB/c-nude mice were employed to analyze the ability 
of tumorigenesis and lung metastasis of 4T1 cells in vivo. 
For assessing tumor incidence and growth, 4T1 cells 
(1.5 ×  106  cells/mice) infected with control-amiRNA or 
Map3k1 amiRNA-3 lentivirus were injected into cleared 
fat pads of BALB/c-nude mice. Mice were examined for 
palpable tumors every 2 days, and the growth of the pri-
mary tumors was measured once a week using a vernier 
caliper. Two perpendicular diameters, termed length (L) 
and width (W), were determined, with length defined 
as the larger of the two measurements. Volume was 
calculated using the formula: 1/2 ×  l ×  W2, Mice were 
euthanized 4 weeks after injection of 4T1 cells. Primary 
tumors were removed and weighed. H&E staining was 
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performed to determine the pathological structure of pri-
mary tumors.
To assess the impact of MAP3K1-targeting miRNA 
on the metastasis of breast cancer, 4T1 cells (5.0 ×  105 
cells/mice) infected with control-amiRNA or Map3k1 
amiRNA-3 lentivirus were transplanted into mice by tail 
vein injection. The weight of mice was measured once a 
week. Mice were euthanized 4  weeks after injection of 
4T1 cells. Metastasis was evaluated in lungs, which is 
typical for this tumor due to their visibility and ease of 
quantification. Lungs were fixed in Bouin’s solution, and 
metastases were quantified by counting on a dissect-
ing microscope. Finally, H&E staining was performed to 
analyze the pathological structure of lung metastasis of 
breast cancer.
Statistics
Data were analyzed using Prism software (GraphPad 
Software, Inc., La Jolla, CA). Values were compared using 
a student’s t test, and a two-sided p value of ≤0.05 was 
considered significant, and ≤0.01 means very significant.
Results
MEKK1 was highly expressed in human breast cancer 
specimens
To explore the involvement of MEKK1 in breast can-
cer development, the expression pattern of MEKK1 was 
first determined using immunohistochemical analysis. 
As shown in Fig.  1a, b, the expression of MEKK1 was 
markedly upregulated in breast cancer tissues, compared 
with adjacent non-tumorous ones. Notably, MEKK1 was 
especially abundantly expressed in invasive breast cancer 
samples. Next, we analyzed the expression of MEKK1 in 
different breast cancer cell lines. Real-time and western 
blot analysis indicated that MEKK1 was also enriched in 
breast cancer cell lines, particularly in marine 4T1 breast 
cancer cells (Fig.  1c–e). Therefore, these data implied 
that MEKK1 might exert a facilitating role in breast 
carcinogenesis.
Overexpression of Map3k1 amiRNA down‑regulated ERK 
signaling in breast cancer cells
Next, we investigated the role of MEKK1 in the regula-
tion of breast cancer growth and invasion. Because recent 
studies highlighted that artificial miRNA could effectively 
target genes to modulate the physiology of cancer cells, 
we designed 5 MAP3K1-targeting miRNAs using Invitro-
gen Block-iT RNAi Designer program, and constructed 
the precursors of the 5 miRNAs into pcDNA™6.2-GW/
EmGFP-miR vector. The constructs have been veri-
fied using PCR analysis and DNA sequencing (Data not 
shown). Thereafter, the constructs were transfected into 
4T1 cells. Using real-time PCR analysis, we found that 
Map3k1 amiRNA-3 achieved the best interference effi-
ciency (Fig. 2a). As predicted, the protein level of MEKK1 
was also dramatically down-regulated after the transfec-
tion of Map3k1 amiRNA-3 (Fig. 2b–d). Because MEKK1 
was documented to activate MAPKs, we detected the 
level of phosphorylated p-38, JNK and ERK in 4T1 cells 
transfected with control-amiRNA or Map3k1 amiRNA-3. 
As shown in Fig.  2e, f, the transfection of Map3k1 
amiRNA-3 decreased the level of phosphorylated ERK 
(p-ERK), and to a less extent, p-38. However, we did not 
observe any alterations in the level of phosphorylated 
JNK in the cells. These findings suggested that artificial 
miRNA-mediated deprivation of MEKK1 could selec-
tively inhibit ERK and p-38 signaling in breast cancer 
cells.
Map3k1 amiRNA attenuated the proliferation of 4T1 breast 
cancer cells
Because ERK and p-38 signaling have been documented 
to regulate the growth and invasion of breast cancer 
cells, we analyzed whether transfection of Map3k1 
amiRNA-3 could influence the growth of breast cancer 
cells. To this end, we constructed Map3k1 amiRNA-3 
precursor into a Lentivirus construct. Thereafter, 
Map3k1 amiRNA Lentivirus was obtained by co-trans-
fection of the Map3k1 amiRNA-3 lentivirus and helper 
vectors. 4T1 cells were infected with control virus or 
Map3k1 amiRNA virus and subjected to real-time PCR 
analysis to determine the level of MAP3K1 mRNA in the 
cells, which indicated that the level of MAP3K1 mRNA 
was apparently decreased after the infection of Map3k1 
amiRNA virus (Data not shown). Next, the cells were 
subjected to EDU incorporation assay to determine the 
proliferation of the cells. As shown in Fig. 3A, B, the rate 
of EDU incorporation declined remarkably after Map3k1 
amiRNA transduction, suggesting that Map3k1 amiRNA 
significantly impaired the proliferation of 4T1 breast 
cancer cells. Furthermore, the colony formation assay 
was performed. Coinciding with the reduced EDU rate, 
the colony formation capacities of Map3k1 amiRNA-
infected cells was evidently impaired, compared with 
control cells (Fig. 3C, D).
Overexpression of Map3k1 amiRNA inhibited the 
migration and invasion of breast cancer cells
Because ERK and p-38 were reported to play regula-
tory roles in the invasion of breast cancer cells, we 
addressed whether overexpression of Map3k1 amiRNA-3 
might inhibit the migration and invasion of breast can-
cer cells (Gomes et al. 2012). Thus, control and Map3k1 
amiRNA-3 overexpressing 4T1 cells were subjected to 
scratch and Matrigel transwell assays. 24 h after scratch, 
control cells exhibited apparent migration into scratched 
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region (Fig.  4A). However, overexpression of Map3k1 
amiRNA-3 significantly impaired the migrating ability of 
the cells (Fig.  4A, B). As predicted, transwell assay also 
revealed that Map3k1 amiRNA-3 overexpression attenu-
ated the number of cells that invaded through Matrigel 
(Fig.  4C, D). Therefore, these results clearly indicated 
that overexpression of Map3k1 amiRNA-3 impaired the 
migration and invasion of 4T1 breast cancer cells.
Overexpression of Map3k1 amiRNA did not affect the 
apoptotic response of breast cancer cells
Furthermore, we analyzed whether the apoptotic 
response were affected after Map3k1 amiRNA-3 overex-
pression. TUNEL assay was employed to determine the 
apoptotic rate of control and Map3k1 amiRNA-overex-
pressing 4T1 cells. As shown in Fig. 5a, b, the two groups 
of cells did not exhibit any difference in the apoptotic 
rate. Thus, Map3k1 amiRNA-3 may not influence the 
apoptotic response of breast cancer cells.
Overexpression of Map3k1 amiRNA alters the growth 
and metastasis of breast cancer cells in vivo
To further delineate the involvement of artificial miRNA-
induced MAP3K1 depletion in breast cancer progres-
sion, we investigated the in vivo growth and metastasis of 
breast cancer cells using nude mice model. Control and 
Map3k1 amiRNA-overexpressing 4T1 cells were injected 
into the flanks of BALB/c nude mice. The sizes of tumors 
were measured weekly, and the growth curves of the 
tumors were produced. As shown in Fig. 6a, b, 4 weeks 
after injection, the tumor size and weight of control cells 
were significantly larger than Map3k1 amiRNA-overex-
pressing cells (Table 1). In addition, the tumors were sub-
jected to HE staining. Map3k1 amiRNA-overexpressing 
Fig. 1 MEKK1 was highly expressed in invasive breast cancer specimens and breast cancer cell lines. a Representative images of MEKK1 expression 
in breast cancer specimens and adjacent normal tissues. upper panel, 20× magnification; lower panel, 40× magnification. b Statistical analysis of 
MEKK1 expression in breast cancer specimens and adjacent normal tissues. c Real-time PCR analysis of MAP3K1 mRNA expression in breast cancer 
cell lines. d Western blot analysis of MEKK1 expression in different breast cancer cell lines. e The bar chart indicates the ratio of MEKK1 protein level 
to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) by densitometry in breast cancer cells (*p < 0.05)
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Fig. 2 Transfection of Map3k1 amiRNA significantly impaired cellular level of MEKK1 and downstream MAPK pathways in breast cancer cells. a Real-
time PCR analysis of the interference efficiencies of different Map3k1 amiRNA constructs. b Time-dependence of MAP3K1 mRNA expression follow-
ing Map3k1 amiRNA transfection using real-time PCR analysis. c Western blot detection of MEKK1 expression after Map3k1 amiRNA transfection. d 
The bar chart indicates the ratio of MEKK1 protein expression to GAPDH using densitometry after Map3k1 amiRNA transfection. e Determining the 
influence of Map3k1 amiRNA-3 overexpression on the levels of p-ERK, p-p38 and p-JNK MAPKs using western blot analysis. f Quantitative analysis of 
the intensities of MAPK protein bands relative to GAPDH in the indicated groups (*p < 0.05, **p < 0.01)
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tumors displayed very clear tumor border and regular 
inner structure. However, in control tumors, necrotic-
like regions were frequently observed, probably because 
the tumors were larger in size and could be easily affected 
by many micro-environmental factors, such as hypoxia 
and nutritional deficiency. Of note, control tumors exhib-
ited invasive behaviors into muscle and fat tissues, which 
were rarely found in Map3k1 amiRNA-overexpressing 
tumors (Fig. 6C).
To further elucidate the role of Map3k1 amiRNA in 
the regulation of breast cancer metastasis, we assessed 
whether Map3k1 amiRNA-3 could impair the ability 
of 4T1 cells to colonize the lungs of Balb/c nude mice. 
4 weeks after cell injection, the mice were sacrificed and 
lung metastasis of breast cancer cells was examined. As 
shown in Fig. 7A, control cells formed many metastatic 
niches in the lungs of nude mice, whereas mice injected 
with Map3k1 amiRNA-overexpressing cells had very 
few tumors in their lungs (Table 2). HE staining analysis 
also revealed that overexpression of Map3k1 amiRNA-3 
reduced the rate of lung metastasis and invasive behav-
ior of breast cancer cells in nude mice xenograft model 
(Fig.  7B). Taken together, these data indicated that 
Map3k1 amiRNA-induced MAP3K1 depletion inhibited 
the growth and lung metastasis of breast cancer cells.
Discussion
The MAPK cascades are central signaling pathways that 
play fundamental roles in many aspects of cellular pro-
cesses, including proliferation, differentiation, migra-
tion and apoptosis. In the present study, we investigated 
the role and potential therapeutic value of MEKK1 in 
Fig. 3 The influence of Map3k1 amiRNA overexpression on the proliferation of 4T1 breast cancer cells. A After Lentivirus infection, control-amiRNA 
and Map3k1 amiRNA-overexpressing 4T1 cells were subjected to EDU incorporation assay. B Statistical analysis of EDU-positive cells in control-
amiRNA and Map3k1 amiRNA-overexpressing cells (*p < 0.05). C Representative images of the colony formation of control-amiRNA and Map3k1 
amiRNA-overexpressing cells in vitro. D Statistical analysis of colony formation capacities of control-amiRNA and Map3k1 amiRNA-overexpressing 
4T1 cells (*p < 0.05)
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Fig. 4 Overexpression of Map3k1 amiRNA impaired the migration and invasion of breast cancer cells. A Scratch assay was performed to deter-
mine the impact of Map3k1 amiRNA-overexpression on the migration of breast cancer cells. B. Statistical analysis of migrated cells during 24 h in 
both control-amiRNA and Map3k1 amiRNA-overexpressing cells (**p < 0.01). C Determination of invasive capacity of control-amiRNA and Map3k1 
amiRNA-overexpressing 4T1 cells using Matrigel transwell assay. D The bar chart indicates the number of invasive cells between control-amiRNA 
and Map3k1 amiRNA-overexpressing groups (*p < 0.05)
Fig. 5 Map3k1 amiRNA did not affect the apoptosis of 4T1 breast cancer cells. a TUNEL assay revealed that 4T1 cells exhibited comparable apop-
totic rate between control-amiRNA and Map3k1 amiRNA-overexpressing groups. b The bar chart shows that the apoptosis of cells did not differ 
statistically between control-amiRNA and Map3k1 amiRNA-overexpressing cells
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breast cancer. We found that MEKK1 was upregulated 
in a majority of breast cancer samples. Of great impor-
tance, we showed that miRNA-based MAP3K1 targeting 
significantly suppressed the proliferation and invasion 
of breast cancer cells. Additionally, using nude mice, we 
identified that Map3k1 amiRNA treatment attenuated 
Fig. 6 Overexpression of Map3k1 amiRNA attenuated the in vivo tumor formation of 4T1 breast cancer cells. A Representative images of tumor 
formation in control-amiRNA and Map3k1 amiRNA-overexpressing cells in nude mice. B The growth curve of control-amiRNA and Map3k1 
amiRNA-overexpressing tumors (*p < 0.05). C HE staining of control-amiRNA and Map3k1 amiRNA-overexpressing tumors indicated that control 
tumors displayed necrotic-like structure, invasion into muscle and fat tissues, whereas similar phenomena were not identified in Map3k1 amiRNA-
overexpressing tumors (a, arrowheads indicated necrotic-like region; b, arrowhead indicated tumor invasion into muscle tissues; c, arrowhead tumor 
invasion into fat tissues)
Table 1 The effect of MEKK1 suppression on tumorigenic capacity of 4T1 cells
Data showed that tumor size and weight of control cells were significantly larger than Map3k1 amiRNA-overexpressing cells (*p < 0.05)
Group Incidence of tumorigenesis Tumor weight (g) Tumor size (cm3)
Ctrl amiRNA 8/8 5.41 ± 1.39 3.26 ± 0.85
Map3k1 amiRNA-3 7/8 3.09 ± 0.54* 2.35 ± 0.25*
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the progression and lung metastasis of breast cancer 
in  vivo. These data undoubtedly supported the notion 
that MEKK1 plays an important role in the regulation 
of breast cancer growth and metastasis, highlighting 
that miRNA-targeted MAP3K1 depletion is a valuable 
approach in the treatment of breast cancer.
In recent years, the development of targeted therapy 
is a most attractive strategy of cancer therapy. In this 
regard, RNA-based modulation of mRNA and protein 
expression has attracted significant research attention 
(Tong et  al. 2005). RNA interference has been widely 
regarded as a promising approach to achieve the goal 
of protein expression modulation (Devi 2006). How-
ever, due to their transient expression and limited 
delivery system in  vivo, the therapeutic efficiencies of 
RNAi oligos remain unsatisfactory (Zhao et  al. 2009). 
In addition, the use of RNA polymerase III as transcrip-
tion machinery is difficult to control their expression 
Fig. 7 Map3k1 amiRNA reduced lung metastasis of 4T1 breast cancer cells. A The formation of lung tumor niches in control-amiRNA and Map3k1 
amiRNA-overexpressing 4T1 cells after tail vein injection. Control-amiRNA 4T1 cells formed significantly higher numbers of tumor niches than 
Map3k1 amiRNA-overexpressing ones (arrowhead pointed to tumor niches). B HE staining was conducted to verify the tumor niches of the two 
groups (a, d, arrowhead indicated the region area of tumor niches formed by control cells were obviously larger than Map3k1 amiRNA-overexpress-
ing cells; b, arrowhead pointed to the metastatic tumor formed by control 4T1 cells in blood vessel of lungs; c, arrowhead indicated inflammatory 
reaction and hyperplasia in lung tissue were occurring in control amiRNA group, whereas Map3k1 amiRNA-3 group maintained a integrated lung 
tissue)
Table 2 The effect of  MEKK1 suppression on  metastatic 
capacity of 4T1 cells
Data showed that control-amiRNA 4T1 cells formed significantly higher numbers 
of tumor niches than Map3k1 amiRNA-overexpressing ones (*p < 0.05)
Group Death rate Incidence 
of metastasis
Nodules/lung
Ctrl amiRNA 4/10 10/10 17 ± 9
Map3k1 amiRNA-3 2/10 8/10 8 ± 5*
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in desired targeting tissues and cells. miRNAs, a class 
of polymerase II-directed endogenous small single-
stranded RNAs (ssRNA) that share similar acting mech-
anism with RNAi, may avoid the limitations. It was 
recently reported that modified shRNA construct using 
miRNA-based processing machinery may offer more 
reliable and profound outcome of gene therapy with few 
side effects in vivo (Stegmeier et al. 2005; McBride et al. 
2008). In the current study, we examined whether a sim-
ilar system may provide favorable result in breast cancer 
treatment. We found that Map3k1 amiRNA conferred 
marked tumor-suppressive and anti-metastatic effects 
through stable MEKK1 depletion in  vitro and in  vivo. 
These findings explicitly infer that artificial miRNA 
may provide considerable therapeutic merit in cancer 
management.
The oncogenic property of MEKK1 was largely attrib-
uted to the activations of downstream MAPK kinases. 
MAPK kinases play complicated roles in the develop-
ment of human cancers. For example, ERK MAPKs are 
activated by a wide range of mitogens and play a pre-
dominant role in promoting the growth and metastasis 
of cancer, including breast cancer (Samatar and Pou-
likakos 2014). Studies have established that ERK was 
responsible for enhanced proliferation and migration of 
breast cancer under many conditions. Bianchi-Smiraglia 
A et al. reported that integrin β5 contributed to malig-
nant proliferation, tumor angiogenesis and metastasis 
of breast cancer through the activation of Src-FAK and 
MEK-ERK signaling pathways (Bianchi-Smiraglia et  al. 
2013). Discoidin domain receptor 2 (DDR2) facilitates 
the metastasis of breast cancer through ERK-mediated 
Snail1 phosphorylation (Zhang et al. 2013). Studies have 
shown that ERK conferred the proliferation of breast 
cancer cells through phosphorylation-dependent down-
regulation and nuclear export of p27 (Foster et al. 2003). 
In addition to Snail and p27, approximate 160 substrates 
of ERK kinase have been identified, many of which are 
critically involved in breast cancer growth and metas-
tasis, such as c-myc, Elk-1 and MSK (Yoon and Seger 
2006). These findings implicated an important role of 
ERK signaling in breast cancer progression and inva-
sion. Coinciding with the notion, our results identified 
that amiRNA-mediated MAP3K1 silencing could sig-
nificantly influence ERK pathway, partially accounting 
for the impaired tumor growth and metastasis. In addi-
tion to ERK, our findings suggested that p38 MAPK, to 
a less extent, was also affected by Map3k1 amiRNA. It 
is noteworthy that p38 also contributes to the prolifera-
tion and metastasis of breast cancer, and inhibition of 
p38 leads to impaired proliferation of ER-negative breast 
cancer cells (Chen et  al. 2009; Kim et  al. 2003). How-
ever, some other studies implicated that p38 activation 
resulted in growth impairment of breast cancer (Coco-
lakis et al. 2001; Yu et al. 2007). Thus, it remains unclear 
about the detailed role of p38 in breast cancer physiol-
ogy following Map3k1 amiRNA overexpression. By con-
trast, JNK signaling is frequently related with apoptotic 
response in cancer cells under stress conditions. Our 
study found that JNK activity was largely unchanged 
after MEKK1 inactivation, which was consistent with 
comparable apoptosis between control and Map3k1 
amiRNA-overexpressing cells. Notably, as mentioned in 
introduction section, MEKK1 also played an important 
role in the regulation of NF-κB signaling, and it is wor-
thy to examine whether NF-κB signaling was altered in 
our experimental settings, because of the central role of 
NF-κB signaling in facilitating the metastasis and growth 
of breast cancer (Huber et al. 2004; Biswas et al. 2004). 
Taken these information into account, we speculated 
that Map3k1 amiRNA may decrease the growth and 
metastasis of breast cancer cells through the regulation 
of multiple signaling pathways.
Conclusions
Taken all the experimental data in vitro and in vivo, we 
for the first time reported that MEKK1 was significantly 
upregulated in breast cancer specimens. Moreover, our 
findings supported that synthetic artificial miRNA that 
targets MAP3K1 exert remarkable growth-inhibitory 
and anti-metastatic effects in breast cancer cells, high-
lighting that artificial miRNA may confer significant 
anti-tumor activity through modulating the expression of 
oncoproteins.
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